Cargando…
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequenc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376749/ https://www.ncbi.nlm.nih.gov/pubmed/28264936 http://dx.doi.org/10.15252/emmm.201606660 |
_version_ | 1782519212200165376 |
---|---|
author | Ajore, Ram Raiser, David McConkey, Marie Jöud, Magnus Boidol, Bernd Mar, Brenton Saksena, Gordon Weinstock, David M Armstrong, Scott Ellis, Steven R Ebert, Benjamin L Nilsson, Björn |
author_facet | Ajore, Ram Raiser, David McConkey, Marie Jöud, Magnus Boidol, Bernd Mar, Brenton Saksena, Gordon Weinstock, David M Armstrong, Scott Ellis, Steven R Ebert, Benjamin L Nilsson, Björn |
author_sort | Ajore, Ram |
collection | PubMed |
description | Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10(−10)), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically. |
format | Online Article Text |
id | pubmed-5376749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53767492017-04-05 Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations Ajore, Ram Raiser, David McConkey, Marie Jöud, Magnus Boidol, Bernd Mar, Brenton Saksena, Gordon Weinstock, David M Armstrong, Scott Ellis, Steven R Ebert, Benjamin L Nilsson, Björn EMBO Mol Med Research Articles Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10(−10)), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically. John Wiley and Sons Inc. 2017-03-06 2017-04 /pmc/articles/PMC5376749/ /pubmed/28264936 http://dx.doi.org/10.15252/emmm.201606660 Text en © 2017 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Ajore, Ram Raiser, David McConkey, Marie Jöud, Magnus Boidol, Bernd Mar, Brenton Saksena, Gordon Weinstock, David M Armstrong, Scott Ellis, Steven R Ebert, Benjamin L Nilsson, Björn Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title_full | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title_fullStr | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title_full_unstemmed | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title_short | Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations |
title_sort | deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with tp53 mutations |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376749/ https://www.ncbi.nlm.nih.gov/pubmed/28264936 http://dx.doi.org/10.15252/emmm.201606660 |
work_keys_str_mv | AT ajoreram deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT raiserdavid deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT mcconkeymarie deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT joudmagnus deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT boidolbernd deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT marbrenton deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT saksenagordon deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT weinstockdavidm deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT armstrongscott deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT ellisstevenr deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT ebertbenjaminl deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations AT nilssonbjorn deletionofribosomalproteingenesisacommonvulnerabilityinhumancancerespeciallyinconcertwithtp53mutations |